ArticleJournal of veterinary internal medicine
Pasireotide for the Medical Management of Feline Hypersomatotropism.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
- Expression of somatostatin receptors in canine and feline meningioma.Veterinary medicine and science · 2024Article
- Feline Comorbidities: Hypersomatotropism-induced diabetes in cats.Journal of feline medicine and surgery · 2024Review
- Method Validation and Establishment of Reference Intervals for an Insulin-like Growth Factor-1 Chemiluminescent Immunoassay in Cats.Veterinary sciences · 2023Article
- Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism.Journal of feline medicine and surgery · 2022Article
- Quality of life and response to treatment in cats with hypersomatotropism: the owners' point of view.Journal of feline medicine and surgery · 2022Article
- Efficacy of hypophysectomy for the treatment of hypersomatotropism-induced diabetes mellitus in 68 cats.Journal of veterinary internal medicine · 2021Article
- Feline Pituitary Adenomas: Correlation of Histologic and Immunohistochemical Characteristics With Clinical Findings and Case Outcome.Veterinary pathology · 2021Article
- Evaluation of hypophysectomy for treatment of hypersomatotropism in 25 cats.Journal of veterinary internal medicine · 2021Article
- Pilot study assessing the use of cabergoline for the treatment of cats with hypersomatotropism and diabetes mellitus.Journal of feline medicine and surgery · 2021Article
- Pituitary Pathology and Gene Expression in Acromegalic Cats.Journal of the Endocrine Society · 2019Article
- Radiotherapy and pasireotide treatment of a growth hormone producing pituitary tumor in a diabetic dog.The Canadian veterinary journal = La revue veterinaire canadienne · 2018Article
- Stereotactic radiation therapy for the treatment of functional pituitary adenomas associated with feline acromegaly.Journal of veterinary internal medicine · 2018Article
- Blood Glucose and Insulin Concentrations after Octreotide Administration in Horses With Insulin Dysregulation.Journal of veterinary internal medicine · 2017Article
- Pasireotide Long-Acting Release Treatment for Diabetic Cats with Underlying Hypersomatotropism.Journal of veterinary internal medicine · 2017Article
- Serum N-Terminal Type III Procollagen Propeptide: An Indicator of Growth Hormone Excess and Response to Treatment in Feline Hypersomatotropism.Journal of veterinary internal medicine · 2016Article
- What's in a Name? Classification of Diabetes Mellitus in Veterinary Medicine and Why It Matters.Journal of veterinary internal medicine · 2016Review
- Transsphenoidal hypophysectomy for the treatment of hypersomatotropism secondary to a pituitary somatotroph adenoma in a dog.Journal of veterinary internal medicineArticle
- Diabetes mellitus remission in a cat with pituitary-dependent hyperadrenocorticism after trilostane treatment.JFMS open reportsArticle
- Medical management of gastrinoma in a cat.JFMS open reportsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeline hypersomatotropism (HST) is a cause of diabetes mellitus in cats. Pasireotide is a novel multireceptor ligand somatostatin analog that improves biochemical control of humans with HST. HYPOTHESIS/
objectivesPasireotide improves biochemical control of HST and diabetes mellitus in cats. ANIMALS: Hypersomatotropism was diagnosed in diabetic cats with serum insulin-like growth factor-1 (IGF-1) concentration >1,000 ng/mL by radioimmunoassay and pituitary enlargement.
methodsInsulin-like growth factor 1 was measured and glycemic control assessed using a 12-hour blood glucose curve on days 1 and 5. On days 2, 3, and 4, cats received 0.03 mg/kg pasireotide SC q12h. IGF-1, insulin dose, and estimated insulin sensitivity (product of the area under the blood glucose curve [BGC] and insulin dose) were compared pre- and post treatment. Paired t-tests or Wilcoxon signed rank tests were employed for comparison where appropriate; a linear mixed model was created to compare BGC results.
resultsInsulin-like growth factor 1 decreased in all 12 cats that completed the study (median [range] day 1: 2,000 ng/mL [1,051-2,000] and day 5: 1,105 ng/mL [380-1,727], P = .002, Wilcoxon signed rank test). Insulin dose was lower on day 5 than on day 1 (mean reduction 1.3 [0-2.7] units/kg/injection, P = .003, paired t-test). The product of insulin dose and area under the BGC was lower on day 5 than day 1 (difference of means: 1,912; SD, 1523; u × mg/dL × hours, P = .001; paired t-test). No clinically relevant adverse effects were encountered.
conclusionsShort-acting pasireotide rapidly decreased IGF-1 in cats with HST and insulin-dependent diabetes. The decrease in IGF-1 was associated with increased insulin sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.